Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence

Nkarta reports strong early efficacy and safety for NKX019 in autoimmune disease trials.

What the company is saying

Nkarta is highlighting positive initial clinical data from its Ntrust program, focusing on its off-the-shelf CAR NK cell therapy, NKX019, for autoimmune diseases. The company emphasizes high response rates in myositis and systemic sclerosis at the 4 billion-cell dose, with 83% and 86% of patients achieving key clinical endpoints, respectively. Safety is framed as a major strength, with no deaths, no treatment discontinuations due to adverse events, and no cases of severe immune complications across 40 patients. CEO Paul J. Hastings positions the results as a milestone, suggesting NKX019 could offer a differentiated and accessible therapy. The announcement stresses outpatient administration and rapid, deep responses, while also noting protocol amendments to test higher doses and compressed dosing schedules. Nkarta is preparing for discussions with the FDA and expects further data and a registrational dose plan in the first half of 2027. The tone is confident, with the company presenting these results as evidence of both clinical promise and a favorable safety profile.

What the data suggests

The disclosed data show that at the 4 billion-cell dose, 83% of myositis patients (5 of 6) achieved moderate or major Total Improvement Score responses, and 86% of systemic sclerosis patients (6 of 7) achieved at least a 25% improvement on the rCRISS scale, with 71% reaching a 50% improvement. In myositis, 50% of evaluable patients saw clinically relevant reductions in skin disease activity. The safety profile is strong: among 40 patients treated across five autoimmune indications and three dose levels, there were no deaths, no treatment discontinuations due to adverse events, and no increase in adverse events at higher doses. Infusion-related reactions occurred in 12.5% of patients, mainly mild and resolving quickly. Deep B-cell depletion was observed, consistent with the intended mechanism. The data are granular, with clear denominators and timepoints, but the sample sizes remain small and the results are early. No financial figures are disclosed, and all numbers pertain to clinical outcomes and patient characteristics. The evidence supports the claim of promising early efficacy and safety, but does not yet establish long-term durability or regulatory readiness.

Analysis

The announcement presents detailed and specific initial clinical data, including response rates and safety outcomes, which are realised and well-supported by the disclosed figures. However, the tone is notably positive, using qualitative descriptors such as 'favorable safety and tolerability profile' without comparative benchmarks. Several forward-looking statements are present, including plans for protocol amendments, upcoming FDA interactions, and future data releases, all of which are projected for 2027 or later, indicating a long execution distance before any potential commercial or regulatory milestone. There is no mention of capital outlay or financial metrics, but as this is a clinical-stage biotech update, this is not a deficiency. The gap between narrative and evidence is moderate: while the realised data is robust for an early-stage trial, the language somewhat overstates the significance by implying broader impact or imminent regulatory progress, when in fact the next steps are still pre-registrational and long-dated.

Risk flags

• ●The small cohort sizes (six to seven patients per key group) limit the statistical power and generalizability of the efficacy and safety findings. Larger studies may reveal lower response rates or new safety issues.
• ●The timeline to potential regulatory approval is long, with the next major update not expected until the first half of 2027. This exposes the program to risks of clinical setbacks, regulatory delays, or changes in the competitive landscape.
• ●No financial data or funding status is disclosed, leaving uncertainty about the company’s ability to sustain operations through the next phases of development and regulatory engagement.
• ●While no severe safety events were reported, the long-term safety of repeated or higher-dose NKX019 administration remains unproven, especially as the protocol moves to 6 billion-cell dosing.
• ●The program’s success depends on future FDA interactions and agreement on registrational pathways, which are not guaranteed and could be delayed or require additional studies.

Bottom line

Nkarta’s initial Ntrust trial data for NKX019 show high early response rates and a clean safety profile in small cohorts of myositis and systemic sclerosis patients, with 83% to 86% achieving key clinical improvements at the highest tested dose. The company is moving quickly to amend protocols and pursue higher dosing, but all milestones remain pre-registrational, with the next major update not due until the first half of 2027. The lack of financial disclosure means investors cannot assess capital runway or funding risk. While these results are promising for a clinical-stage biotech, the path to commercial value is still long, and the findings must be confirmed in larger, longer-term studies and through regulatory engagement. The most important takeaway is that NKX019 is demonstrating early clinical potential, but the investment case hinges on future data and regulatory clarity.

Announcement summary

(NASDAQ:NKTX) Nkarta announced positive initial clinical data from its Ntrust clinical trial program evaluating NKX019, an allogeneic, off-the-shelf CAR NK cell therapy candidate, in autoimmune diseases. The initial data, as of the September 18, 2026 ACR data cutoff, were presented at the American College of Rheumatology (ACR) Convergence 2026 in two oral presentations and one poster, focusing on myositis and systemic sclerosis. Patients at the 4 billion-cell dose level received three doses of NKX019 on Days 0, 3, and 7, totaling 12 billion cells. In myositis, five of six patients (83%) treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major Total Improvement Score (TIS) responses, and five of six (83%) showed improvements in muscle strength. Four of eight evaluable patients (50%) achieved clinically relevant reductions in skin disease activity. In systemic sclerosis, six of seven patients (86%) treated at 4 billion cells per dose with at least three months of follow-up achieved an rCRISS-25 response or greater, and five of seven (71%) achieved an rCRISS-50 response or greater. Median improvement in modified Rodnan skin score (mRSS) was 15 points at Day 90, with six of seven (86%) showing reduction and five of seven (71%) achieving at least 50% reduction from baseline. Among 40 patients treated across five autoimmune indications and three dose levels, NKX019 demonstrated a favorable safety and tolerability profile, with no deaths, no treatment discontinuations due to adverse events, and no increase in adverse events at higher doses. There were no reported cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus-host disease (GvHD), and no cases of leukoencephalopathy. Infusion-related reactions occurred in five patients (12.5%), mostly grade 1, all resolving within 24 to 48 hours. Deep peripheral CD19+ B-cell depletion was observed at the 4 billion-cell dose, with median B-cell counts remaining depleted through Day 27 (n=22). Early evidence of a dose response was observed, with more consistent clinical responses at 4 billion cells per dose compared to lower doses (1 billion and 2 billion). In myositis, nine of eleven patients (82%) in the baseline efficacy population had received four or more prior therapies, and in systemic sclerosis, nine of fourteen (64%) had received at least three prior therapies. Nkarta recently amended the Ntrust protocols to compress dosing to Days 0, 2, and 4, and plans to evaluate 6 billion cells per dose. The company anticipates upcoming interactions with the U.S. Food and Drug Administration to discuss potential registrational pathways in both indications. Additional clinical follow-up and a plan for registrational dose selection are expected in the first half of 2027. The Ntrust-1 (NCT06557265) and Ntrust-2 (NCT06733935) trials are multi-center, open-label, dose-escalation studies enrolling up to 12 patients per dose level per disease indication, with additional patients possible to refine populations for further study. Patients receive a three-dose cycle of NKX019 following lymphodepleting preconditioning with fludarabine and cyclophosphamide or cyclophosphamide alone. Patients may receive additional cycles if needed to restore or deepen response.

Disagree with this article?